Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 14, 2014, Pages 5409-5414

  Wollberg, Anna Ridderstad ^a   Ericsson Dahlstrand, Anders ^a   Juréus, Anders ^a   Ekerot, Petra ^a   Simon, Sylvia ^a   Nilsson, Maria ^a   Wiklund, Stig Johan ^a   Berg, Anna Lena ^a   Ferm, Mats ^a   Sunnemark, Dan ^a   Johansson, Rolf ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Fractalkine receptor; Inflammation

Indexed keywords

AZD 8797; CD68 ANTIGEN; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CX3CR1; MESSENGER RNA; MYELIN; UNCLASSIFIED DRUG;

ACTIN POLYMERIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BRAIN DAMAGE; CELL INFILTRATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATORY CELL; LEUKOCYTE; MACROPHAGE; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PHARMACOLOGICAL BLOCKING; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

FRACTALKINE RECEPTOR; INFLAMMATION;

ANIMALS; BRAIN; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; MULTIPLE SCLEROSIS; RATS; RECEPTORS, CHEMOKINE; RECURRENCE;

EID: 84898041245     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1316510111     Document Type: Article

References (33)

1. Mix E, Meyer-Rienecker H, Hartung HP, Zettl UK (2010) Animal models of multiple sclerosis-potentials and limitations. Prog Neurobiol 92(3):386-404.
2. 't Hart BA, Gran B, Weissert R (2011) EAE: Imperfect but useful models of multiple sclerosis. Trends Mol Med 17(3):119-125.
3. Holman DW, Klein RS, Ransohoff RM (2011) The blood-brain barrier, chemokines and multiple sclerosis. Biochim Biophys Acta 1812(2):220-230.
4. Fujino M, et al. (2003) Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 305(1):70-77.
5. Yednock TA, et al. (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356(6364):63-66.
6. Barten LJ, Allington DR, Procacci KA, Rivey MP (2010) New approaches in the management of multiple sclerosis. Drug Des Devel Ther 4:343-366.
7. Rudick R, Polman C, Clifford D, Miller D, Steinman L (2013) Natalizumab: Bench to bedside and beyond. JAMA Neurol 70(2):172-182.
8. Buck D, Hemmer B (2011) Treatment of multiple sclerosis: Current concepts and future perspectives. J Neurol 258(10):1747-1762.
9. Hellwig K, Gold R (2011) Progressive multifocal leukoencephalopathy and natalizumab. J Neurol 258(11):1920-1928.
10. Frischer JM, et al. (2009) The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132(Pt 5):1175-1189.
11. D'Haese JG, Demir IE, Friess H, Ceyhan GO (2010) Fractalkine/CX3CR1: Why a single chemokine-receptor duo bears a major and unique therapeutic potential. Expert Opin Ther Targets 14(2):207-219.
12. Springer TA (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 76(2):301-314.
13. Foussat A, et al. (2000) Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human. Eur J Immunol 30(1): 87-97.
14. Nishimura M, et al. (2002) Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol 168(12):6173-6180.
15. Robertson MJ (2002) Role of chemokines in the biology of natural killer cells. J Leukoc Biol 71(2):173-183.
16. Ancuta P, et al. (2003) Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 197(12):1701-1707.
17. Sunnemark D, et al. (2003) Differential expression of the chemokine receptors CX3CR1 and CCR1 by microglia and macrophages in myelin- oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis. Brain Pathol 13(4): 617-629.
18. Karlström S, et al. (2013) Substituted 7-amino-5-thio-thiazolo[4,5- d]pyrimidines as potent and selective antagonists of the fractalkine receptor (CX3CR1). J Med Chem 56(8):3177-3190.
19. Papadopoulos D, Pham-Dinh D, Reynolds R (2006) Axon loss is responsible for chronic neurological deficit following inflammatory demyelination in the rat. Exp Neurol 197(2):373-385.
20. Storch MK, et al. (1998) Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 8(4):681-694.
21. Hughes PM, Botham MS, Frentzel S, Mir A, Perry VH (2002) Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS. Glia 37(4):314-327.
22. Weissert R, et al. (1998) MHC haplotype-dependent regulation of MOG-induced EAE in rats. J Clin Invest 102(6):1265-1273.
23. Batarseh A, Papadopoulos V (2010) Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states. Mol Cell Endocrinol 327(1-2):1-12.
24. Dichmann S, et al. (2001) Fractalkine induces chemotaxis and actin polymerization in human dendritic cells. Inflamm Res 50(11):529-533.
25. Wulf E, Deboben A, Bautz FA, Faulstich H, Wieland T (1979) Fluorescent phallotoxin, a tool for the visualization of cellular actin. Proc Natl Acad Sci USA 76(9):4498-4502.
26. Cardona AE, et al. (2006) Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 9(7):917-924.
27. Huang D, et al. (2006) The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J 20(7):896-905.
28. Garcia JA, et al. (2013) Regulation of adaptive immunity by the fractalkine receptor during autoimmune inflammation. J Immunol 191(3):1063-1072.
29. Haskell CA, et al. (2001) Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest 108(5):679-688.
30. Balatoni B, et al. (2007) FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 74(5):307-316.
31. Papadopoulos D, et al. (2010) FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses. J Neurosci Res 88(2):346-359.
32. Sunnemark D, et al. (2005) CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: Kinetics and cellular origin. J Neuroinflammation 2:17.
33. Pruenster M, et al. (2009) The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity. Nat Immunol 10(1):101-108.